Jeffrey S Farrow
CIK 1405253 · See Remarks · last filed 2026-07-29
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
GBT price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
SOUTH SAN FRANCISCO, CA 94080
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ACHV | Director | — | $6.78 | — | $0 | 2 | 2026-07-29 |
| TARS | See Remarks | 56,801 | $78.00 | $4.43M | -$2.33M | 11 | 2026-06-17 |
| Global Blood Therapeutics, Inc. (GBT) Delisted | Chief Financial Officer | 0 | $68.49 | $0 | -$4.30M | 29 | 2022-10-06 |
| HYPERION THERAPEUTICS INC (HPTX) Delisted | CFO | 0 | — | — | $0 | 7 | 2015-05-08 |
| RENOVIS INC (RNVS) Delisted | V.P., Finance and CAO | 62,286 | — | — | $0 | 3 | 2008-02-12 |
Recent Filings · Page 5 of 7
63 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2019-04-10 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +1,308 | -$40.5K | EDGAR |
| 2019-02-05 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +3,774 | -$104.8K | EDGAR |
| 2018-11-28 | Global Blood Therapeutics, Inc. (GBT) Delisted | Exer (M) | +3,048 | $50.0K | EDGAR |
| 2018-08-03 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +3,537 | -$103.6K | EDGAR |
| 2018-02-16 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +1,308 | -$43.1K | EDGAR |
| 2018-02-02 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +3,311 | -$103.2K | EDGAR |
| 2018-01-26 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +1,317 | -$39.7K | EDGAR |
| 2018-01-18 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +1,123 | -$45.7K | EDGAR |
| 2017-08-14 | Global Blood Therapeutics, Inc. (GBT) Delisted | Grant (A) | — | $0 | EDGAR |
| 2017-08-03 | Global Blood Therapeutics, Inc. (GBT) Delisted | Mixed | +1,911 | -$28.9K | EDGAR |
10b5-1: the filer ticked the box for trades made under a Rule 10b5-1 trading plan, which sets the sales (or buys) in advance, so they say less about the insider's view at the time than a discretionary trade. The plan's adoption date is shown when the filing's footnotes give it.
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment, and an amended or cancelled notice is not listed. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes. Someone who is no longer an officer or director (or never was) files no Form 4, so for them a sale shows up only on a later notice, which lists the seller's sales from the 3 months before it. "No sale on file" means neither record shows one; a dash in Net $ means the value filed on the notice doesn't fit the stock's price (likely a typo).